Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MaaT 013

Next Previous
Drug Profile

MaaT 013

Alternative Names: MaaT-013; Xervyteg

Latest Information Update: 11 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MaaT Pharma
  • Developer Assistance Publique Hopitaux de Paris; MaaT Pharma
  • Class Antineoplastics; Bacteria; Immunotherapies
  • Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Graft-versus-host disease
  • Phase II Malignant melanoma
  • Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 02 Jun 2025 Preregistration for Graft-versus-host disease (Treatment-resistant) in European Union (Rectal)
  • 02 Jun 2025 MaaT Pharma anticipates potential approval for Graft-versus-host disease in second half of 2026
  • 28 May 2025 No recent reports of development identified for clinical-Phase-Unknown development in Graft-versus-host-disease(Treatment-resistant) in Canada (Rectal, Enema)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top